ENANTA PHARMACEUTICALS INC (ENTA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue Annual

0 80M 160M 240M FY16: 88.3M FY17: 102.8M FY18: 206.6M FY19: 205.2M FY20: 122.5M FY21: 97.1M FY22: 86.2M FY23: 79.2M FY24: 67.6M FY25: 65.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-150M -100M -50M 0 50M 100M 150M FY16: 30.8M FY17: 24.6M FY18: 88.3M FY19: 36.7M FY20: -41.6M FY21: -109.6M FY22: -123.8M FY23: -137.2M FY24: -121.7M FY25: -85.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-150M -100M -50M 0 50M 100M 150M FY17: 17.7M FY18: 72M FY19: 46.4M FY20: -36.2M FY21: -79M FY22: -121.8M FY22: -121.8M FY23: -133.8M FY24: -116M FY25: -81.9M FY17 FY18 FY19 FY20 FY21 FY22 FY22 FY23 FY24 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-120M -80M -40M 0 40M 80M 120M FY16: 35.8M FY17: 52.7M FY18: 29.2M FY19: 71.4M FY20: 7.1M FY21: -70M FY22: -84.8M FY23: -103.2M FY24: -78.8M FY25: -19.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-120M -80M -40M 0 40M 80M 120M FY16: 31.1M FY17: 50.1M FY18: 26.2M FY19: 66M FY20: 5.6M FY21: -70.7M FY22: -86.9M FY23: -112.2M FY24: -96.7M FY25: -32.2M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 8M 16M 24M FY16: 19.2M FY17: 19.4M FY18: 20.6M FY19: 21M FY20: 19.9K FY21: 20.2K FY22: 20.6K FY23: 21K FY24: 21.2K FY25: 21.3K FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '16: 1.12 Q1 '17: -0.50 Q2 '17: -0.69 Q3 '17: -1.07 Q4 '17: 0.88 Q1 '18: 1.73 Q2 '18: 2.62 Q3 '18: 4.03 Q4 '18: 3.47 Q1 '19: 4.13 Q2 '19: 3.72 Q3 '19: 3.08 Q4 '19: 2.22 Q1 '20: 1.62 Q2 '20: 1.12 Q3 '20: 0.08 Q4 '20: -1.82 Q1 '21: -2.88 Q2 '21: -3.67 Q3 '21: -4.15 Q4 '21: -3.91 Q1 '22: -4.98 Q2 '22: -5.52 Q3 '22: -5.86 Q4 '22: -5.91 Q1 '23: -5.82 Q2 '23: -5.98 Q3 '23: -6.31 Q4 '23: -6.37 Q1 '24: -6.56 Q2 '24: -6.24 Q3 '24: -5.45 Q4 '24: -5.48 Q1 '25: -4.95 Q2 '25: -4.54 Q3 '25: -4.32 Q4 '25: -3.84 Q1 '26: -3.21 Q2 '26: -2.60 Q3 '26: -2.42 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.